BTIG Research Begins Coverage on Definitive Healthcare (NASDAQ:DH)

BTIG Research initiated coverage on shares of Definitive Healthcare (NASDAQ:DH) in a note issued to investors on Tuesday, Briefing.com reports. The firm set a “buy” rating and a $7.00 price target on the stock. BTIG Research’s price objective would suggest a potential upside of 57.66% from the company’s current price.

Several other brokerages also recently weighed in on DH. JPMorgan Chase & Co. downgraded shares of Definitive Healthcare from a “neutral” rating to an “underweight” rating and decreased their target price for the stock from $7.00 to $5.00 in a research note on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Definitive Healthcare from $7.00 to $5.00 and set a “hold” rating for the company in a research report on Friday, August 9th. Morgan Stanley lowered their price objective on shares of Definitive Healthcare from $9.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 6th. Stifel Nicolaus cut their price target on Definitive Healthcare from $9.50 to $7.50 and set a “buy” rating for the company in a report on Wednesday, July 31st. Finally, Barclays reduced their price objective on shares of Definitive Healthcare from $6.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Definitive Healthcare has an average rating of “Hold” and an average price target of $5.81.

Definitive Healthcare Price Performance

Definitive Healthcare stock opened at $4.44 on Tuesday. Definitive Healthcare has a 1 year low of $3.19 and a 1 year high of $10.62. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.40 and a current ratio of 2.40. The company’s fifty day moving average price is $4.67 and its 200 day moving average price is $5.95. The stock has a market capitalization of $523.63 million, a P/E ratio of -2.54, a P/E/G ratio of 6.38 and a beta of 1.33.

Definitive Healthcare (NASDAQ:DH) last issued its earnings results on Monday, August 5th. The company reported $0.09 EPS for the quarter, hitting analysts’ consensus estimates of $0.09. Definitive Healthcare had a negative net margin of 156.65% and a positive return on equity of 0.98%. The company had revenue of $63.70 million for the quarter, compared to the consensus estimate of $63.19 million. During the same period in the previous year, the firm earned $0.08 earnings per share. Definitive Healthcare’s quarterly revenue was up 4.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Definitive Healthcare will post 0.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Norden Group LLC bought a new position in shares of Definitive Healthcare during the 1st quarter worth about $83,000. Sanctuary Advisors LLC bought a new stake in shares of Definitive Healthcare during the 2nd quarter valued at $85,000. Canada Pension Plan Investment Board acquired a new position in Definitive Healthcare in the second quarter valued at about $109,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Definitive Healthcare by 31.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,292 shares of the company’s stock worth $116,000 after acquiring an additional 5,083 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Definitive Healthcare in the 1st quarter valued at $120,000. Institutional investors and hedge funds own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.